KITE-222 is a gene-modified cell therapy commercialized by Gilead Sciences, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KITE-222’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for KITE-222 is expected to reach an annual total of $121 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

KITE-222 Overview

KITE-222 is under development for the treatment of mantle cell lymphoma, recurrent chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia , diffuse large b-cell lymphoma, acute lymphocytic leukemia, Burkitt lymphoma, primary mediastinal b-cell lymphoma. The therapeutic candidate is composed of next-generation chimeric antigen receptor (CAR) T cells targeted against C-type lectin-like molecule-1 (CLL-1) and is developed based on engineered autologous cell therapy (eACT) platform. It is administered through intravenous route.

The therapeutic candidate was under development for the treatment of relapsed and refractory acute myeloid leukemia (AML),

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. It markets its products through commercial teams, third-party distributors and corporate partners. Gilead’s commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$27,116 million for the fiscal year ended December 2023 (FY2023), a decrease of 0.6% over FY2022. In FY2023, the company’s operating margin was 28%, compared to an operating margin of 26.9% in FY2022. In FY2023, the company recorded a net margin of 20.9%, compared to a net margin of 16.8% in FY2022. The company reported revenues of US$6,686 million for the first quarter ended March 2024, a decrease of 6% over the previous quarter.

For a complete picture of KITE-222’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.